Safety and Efficacy of SOF/VEL/VOX FDC for 8 Weeks and SOF/VEL for 12 Weeks in Adults Chronic Genotype 3 HCV Infection and Cirrhosis
POLARIS-3
A Phase 3, Global, Multicenter, Randomized, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination for 8 Weeks and Sofosbuvir/Velpatasvir for 12 Weeks in Subjects With Chronic Genotype 3 HCV Infection and Cirrhosis
2 other identifiers
interventional
220
8 countries
70
Brief Summary
The primary objective of this study is to evaluate the efficacy, safety, and tolerability of treatment with sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) fixed-dose combination (FDC) for 8 weeks and of treatment with sofosbuvir/velpatasvir (SOF/VEL) FDC for 12 weeks in participants naive to direct-acting antivirals (DAA) with chronic genotype 3 hepatitis C virus (HCV) infection and cirrhosis.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for phase_3
Started Dec 2015
Shorter than P25 for phase_3
70 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
December 21, 2015
CompletedStudy Start
First participant enrolled
December 23, 2015
CompletedFirst Posted
Study publicly available on registry
December 24, 2015
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 12, 2016
CompletedStudy Completion
Last participant's last visit for all outcomes
January 2, 2017
CompletedResults Posted
Study results publicly available
November 14, 2017
CompletedMarch 5, 2019
November 1, 2017
10 months
December 21, 2015
October 10, 2017
February 8, 2019
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)
SVR12 was defined as HCV RNA \< the lower limit of quantitation (LLOQ) at 12 weeks after stopping study treatment.
Posttreatment Week 12
Percentage of Participants Who Permanently Discontinue Study Drug Due to an Adverse Event
Up to 12 weeks
Secondary Outcomes (4)
Percentage of Participants With SVR at 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)
Posttreatment Weeks 4 and 24
Percentage of Participants With HCV RNA < LLOQ On Treatment
Weeks 1, 2, 4, 8 and 12
Change From Baseline in HCV RNA
Weeks 1, 2, 4, 8 and 12
Percentage of Participants With Virologic Failure
Up to Posttreatment Week 24
Study Arms (2)
SOF/VEL/VOX
EXPERIMENTALSOF/VEL/VOX tablet for 8 weeks
SOF/VEL
EXPERIMENTALSOF/VEL tablet for 12 weeks
Interventions
400/100/100 mg FDC tablet administered orally once daily with food
400/100 mg FDC tablet administered orally once daily without regard to food
Eligibility Criteria
You may qualify if:
- Willing and able to provide written informed consent
- HCV RNA ≥ 10\^4 IU/mL at screening
- Chronic genotype 3 HCV infection (≥ 6 months)
- Presence of cirrhosis
- HCV treatment naive or treatment experienced with an interferon (IFN)-based regimen
- Use of protocol specified methods of contraception
You may not qualify if:
- Current or prior history of clinically significant illness that may interfere with participation in the study
- Screening ECG with clinically significant abnormalities
- Laboratory parameters outside the acceptable range at screening
- Pregnant or nursing female
- Chronic liver disease not caused by HCV
- Infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Gilead Scienceslead
Study Sites (70)
Unknown Facility
Long Beach, California, United States
Unknown Facility
Los Angeles, California, United States
Unknown Facility
Palo Alto, California, United States
Unknown Facility
Rialto, California, United States
Unknown Facility
San Diego, California, United States
Unknown Facility
San Francisco, California, United States
Unknown Facility
Aurora, Colorado, United States
Unknown Facility
Miami, Florida, United States
Unknown Facility
Wellington, Florida, United States
Unknown Facility
Atlanta, Georgia, United States
Unknown Facility
Indianapolis, Indiana, United States
Unknown Facility
Bastrop, Louisiana, United States
Unknown Facility
Baltimore, Maryland, United States
Unknown Facility
Catonsville, Maryland, United States
Unknown Facility
Boston, Massachusetts, United States
Unknown Facility
Ann Arbor, Michigan, United States
Unknown Facility
Detroit, Michigan, United States
Unknown Facility
Hillsborough, New Jersey, United States
Unknown Facility
New York, New York, United States
Unknown Facility
The Bronx, New York, United States
Unknown Facility
Asheville, North Carolina, United States
Unknown Facility
Fayetteville, North Carolina, United States
Unknown Facility
Pittsburgh, Pennsylvania, United States
Unknown Facility
Providence, Rhode Island, United States
Unknown Facility
Nashville, Tennessee, United States
Unknown Facility
San Antonio, Texas, United States
Unknown Facility
Murray, Utah, United States
Unknown Facility
Norfolk, Virginia, United States
Unknown Facility
Richmond, Virginia, United States
Unknown Facility
Seattle, Washington, United States
Unknown Facility
Camperdown, New South Wales, Australia
Unknown Facility
Darlinghurst, New South Wales, Australia
Unknown Facility
Herston, Queensland, Australia
Unknown Facility
Clayton, Victoria, Australia
Unknown Facility
Fitzroy, Victoria, Australia
Unknown Facility
Melbourne, Victoria, Australia
Unknown Facility
Calgary, Alberta, Canada
Unknown Facility
Edmonton, Alberta, Canada
Unknown Facility
Vancouver, British Columbia, Canada
Unknown Facility
Brampton, Ontario, Canada
Unknown Facility
Toronto, Ontario, Canada
Unknown Facility
Bobigny, France
Unknown Facility
Clermont-Ferrand, France
Unknown Facility
Clichy, France
Unknown Facility
Créteil, France
Unknown Facility
Limoges, France
Unknown Facility
Lyon, France
Unknown Facility
Marseille, France
Unknown Facility
Montpellier, France
Unknown Facility
Nice, France
Unknown Facility
Orléans, France
Unknown Facility
Paris, France
Unknown Facility
Pessac, France
Unknown Facility
Rennes, France
Unknown Facility
Strasbourg, France
Unknown Facility
Vandœuvre-lès-Nancy, France
Unknown Facility
Berlin, Germany
Unknown Facility
Bonn, Germany
Unknown Facility
Cologne, Germany
Unknown Facility
Frankfurt am Main, Germany
Unknown Facility
Hamburg, Germany
Unknown Facility
Hanover, Germany
Unknown Facility
Grafton, Auckland, New Zealand
Unknown Facility
Christchurch, New Zealand
Unknown Facility
San Juan, Puerto Rico
Unknown Facility
London, United Kingdom
Unknown Facility
Manchester, United Kingdom
Unknown Facility
Nottingham, United Kingdom
Unknown Facility
Oxford, United Kingdom
Unknown Facility
Portsmouth, United Kingdom
Related Publications (2)
Foster GR, Thompson AJ, Ruane PJ, Borgia SM, Dore G, Workowski K, et al. A Randomized Phase 3 Trial of Sofosbuvir/Velpatasvir/Voxilaprevir for 8 Weeks and Sofosbuvir/Velpatasvir for 12 Weeks for Patients with Genotype 3 HCV Infection and Cirrhosis: The POLARIS-3 Study [Abstract 258]. J Hepatology 2016;63 (1S):135A
RESULTJacobson IM, Lawitz E, Gane EJ, Willems BE, Ruane PJ, Nahass RG, Borgia SM, Shafran SD, Workowski KA, Pearlman B, Hyland RH, Stamm LM, Svarovskaia E, Dvory-Sobol H, Zhu Y, Subramanian GM, Brainard DM, McHutchison JG, Brau N, Berg T, Agarwal K, Bhandari BR, Davis M, Feld JJ, Dore GJ, Stedman CAM, Thompson AJ, Asselah T, Roberts SK, Foster GR. Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials. Gastroenterology. 2017 Jul;153(1):113-122. doi: 10.1053/j.gastro.2017.03.047. Epub 2017 Apr 5.
PMID: 28390869RESULT
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Results Point of Contact
- Title
- Clinical Trial Disclosures
- Organization
- Gilead Sciences
Study Officials
- STUDY DIRECTOR
Gilead Study Director
Gilead Sciences
Publication Agreements
- PI is Sponsor Employee
- No
- Restriction Type
- OTHER
- Restrictive Agreement
- Yes
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
December 21, 2015
First Posted
December 24, 2015
Study Start
December 23, 2015
Primary Completion
October 12, 2016
Study Completion
January 2, 2017
Last Updated
March 5, 2019
Results First Posted
November 14, 2017
Record last verified: 2017-11
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, SAP
- Time Frame
- 18 months after study completion
- Access Criteria
- A secured external environment with username, password, and RSA code.
Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gilead.com/about/ethics-and-code-of-conduct/policies.